PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Evive Biotech and Acrotech Biopharma Announce FDA
WEBNov 23, 2023 · – Ryzneuta ® is the first non-pegylated granulocyte colony-stimulating factor approved by both the US Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA) for treatment for CIN – Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti ...
CureVac Announces Positive Phase 2 Interim Data from COVID-19 …
WEBJan 8, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
US FDA approves Idorsia’s once-daily TRYVIO ... - Pipelinereview
WEBMar 20, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Capstan Therapeutics Announces $175M Oversubscribed Series B …
WEBMar 20, 2024 · The proceeds from the Series B financing will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline. CPTX2309, a product of Capstan’s tLNP platform, delivers an …
Tirzepatide reduced the risk of developing type 2 diabetes by 94
WEBAug 21, 2024 · 176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the longest completed trial of tirzepatide to date. Tirzepatide resulted in sustained weight loss through the treatment period, averaging a 22.9% decrease in body weight with the
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) …
WEB4 days ago · – TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) – For children aged 5-11 years TransCon CNP demonstrated a change from baseline AGV superior to placebo with LS mean treatment difference of 1.78 cm/year at Week 52 (p<0.
Boehringer’s nerandomilast meets primary endpoint in pivotal …
WEB4 days ago · INGELHEIM, Germany I September 16, 2024 I Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] (FVC) at week 52 versus placebo. FVC is a measure of lung function. 1 Based on these ...
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy …
WEB6 days ago · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
GlycoNex Successfully Completes Phase 1 Study of
WEBAug 19, 2024 · GlycoNex plans to initiate Phase 3 clinical program of SPD8 in osteoporosis, targeting a multibillion USD global market opportunity. NEW TAIPEI CITY, Taiwan I August 19, 2024 I GlycoNex (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer therapies, today announced the successful completion of a Phase 1 clinical ...